ResearcherOklahoma City VA Medical CenterNo recent work listed
Daniel J. Brackett
Matched on OpenAlex author ID A5109126432. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2011: 2 papers · 2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper
Papers 6
- Expression Profiling Identifies the Noncoding Processed Transcript of HNRNPU with Proliferative Properties in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ncrna3030024↗
- Globally increased ultraconserved noncoding RNA expression in pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.10242↗
- Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling. Co-author DOI 10.1016/j.canlet.2015.01.035↗
- Utility of nuclear magnetic resonance spectroscopy for pancreatic cancer studies. Last author DOI 10.1097/mpa.0b013e31822a708c↗
- miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Co-author DOI 10.1016/j.bbrc.2011.02.065↗
- Distinguishing early-stage pancreatic cancer patients from disease-free individuals using serum profiling. Co-author DOI 10.3109/07357907.2010.543214↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Jinmai Jiang · 3 shared papers, 2011–2017 · strength 0.15
- Paper Expression Profiling Identifies the Noncoding Processed Transcript of HNRNPU with Proliferative Properties in Pancreati… DOI 10.3390/ncrna3030024↗
- Paper Globally increased ultraconserved noncoding RNA expression in pancreatic adenocarcinoma. DOI 10.18632/oncotarget.10242↗
- Paper miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. DOI 10.1016/j.bbrc.2011.02.065↗
- Thomas D. Schmittgen · 3 shared papers, 2011–2017 · strength 0.15
- Paper Expression Profiling Identifies the Noncoding Processed Transcript of HNRNPU with Proliferative Properties in Pancreati… DOI 10.3390/ncrna3030024↗
- Paper Globally increased ultraconserved noncoding RNA expression in pancreatic adenocarcinoma. DOI 10.18632/oncotarget.10242↗
- Paper miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. DOI 10.1016/j.bbrc.2011.02.065↗
- Ana Clara P. Azevedo‐Pouly · 2 shared papers, 2016–2017 · strength 0.12
- Dhruvitkumar S. Sutaria · 2 shared papers, 2016–2017 · strength 0.12
- James Randolph Sanders Hocker · 2 shared papers, 2011–2015 · strength 0.07
- Paper Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profil… DOI 10.1016/j.canlet.2015.01.035↗
- Paper Distinguishing early-stage pancreatic cancer patients from disease-free individuals using serum profiling. DOI 10.3109/07357907.2010.543214↗
- Jay S. Hanas · 2 shared papers, 2011–2015 · strength 0.07
- Paper Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profil… DOI 10.1016/j.canlet.2015.01.035↗
- Paper Distinguishing early-stage pancreatic cancer patients from disease-free individuals using serum profiling. DOI 10.3109/07357907.2010.543214↗
- George A. Călin · 1 shared paper, 2016 · strength 0.05
- Yasvir A. Tesiram · 1 shared paper, 2012 · strength 0.04
- Jong Kook Park · 1 shared paper, 2011 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.